
|Videos|February 16, 2023
Case 3: Faricimab in a neovascular nAMD patient with persistent fluid
Advertisement
Dr. Khanani discusses how switching to faricimab helped resolve persistent intraretinal and subretinal fluid in a patient and extended treatment intervals leading to decreased patient burden.
Sponsored by Roche
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
FLORetina 2025: New horizons in research and risk management for ROP
2
FLORetina 2025: Remotely managing patients with neovascular age-related macular degeneration
3
FLORetina 2025: Enrico Borrelli on reframing retinal disease through the lens of choroidal health
4
FLORetina 2025: Antithrombotic use examined in wet AMD submacular hemorrhage
5












































